A. M. Pedersen

Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor α.

A. Lykkesfeldt, A. M. Pedersen, S. Thrane, 2014, International journal of oncology.

A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells

A. Laenkholm, B. Rasmussen, A. Duun-Henriksen, 2014, Oncogene.

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane

A. Lykkesfeldt, J. Lundqvist, A. M. Pedersen, 2015, International journal of oncology.

Presence of the vitamin D inactivating enzyme CYP24A1 in human sperm and prediction of the success of intrauterine insemination: A prospective study

A. Juul, A. Berg, U. Bentin-Ley, 2019, The Journal of Steroid Biochemistry and Molecular Biology.

Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells

A. Lykkesfeldt, A. M. Pedersen, Stine Hole, 2015, Breast Cancer Research and Treatment.